Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Active Biotech regains rights of laquinimod from Teva
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
First patient enrolled in Phase II study evaluating laquinimod
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Teva launches personalised digital support for MS patients - PMLiVE
Patient enrollment in Phase III trial of laquinimod completed
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Laquinimod - Wikipedia
Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Linomide - Wikipedia
CONFIDENTIAL DRAFT: Failure Scenario (PEP Not Achieved)
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
